Diarylalkylamine REV-ERB antagonists and their use as medicaments

Fondazione Istituto Italiano di Tecnologia; Benedetto GRIMALDI; Esther TORRENTE; Rita SCARPELLI; Giovanni BOTTEGONI; Tiziano BANDIERA; Marina VERONESI

Diarylalkylamine REV-ERB antagonists and their use as medicaments

Fondazione Istituto Italiano di Tecnologia (Inventor)
, Benedetto GRIMALDI (Inventor)
, Esther TORRENTE (Inventor)
, Rita SCARPELLI (Inventor)
, Giovanni BOTTEGONI (Inventor)
, Tiziano BANDIERA (Inventor)
, Marina VERONESI (Inventor)

Pharmacy

Research output: Patent

Abstract

The present invention relates to compounds of Formula (I) or pharmaceutically acceptable salts or solvates thereof : It further discloses a pharmaceutical composition comprising the compounds of Formula (I) and their uses as anti-proliferative and pro-apoptotic agents for cancer therapy.

Original language	English
Patent number	WO2015/52283
Publication status	Published - 2015

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

@misc{59d0f1458cc949feb7ce6d6e9ecae5bb,

title = "Diarylalkylamine REV-ERB antagonists and their use as medicaments",

abstract = "The present invention relates to compounds of Formula (I) or pharmaceutically acceptable salts or solvates thereof : It further discloses a pharmaceutical composition comprising the compounds of Formula (I) and their uses as anti-proliferative and pro-apoptotic agents for cancer therapy.",

author = "\{Fondazione Istituto Italiano di Tecnologia\} and Benedetto GRIMALDI and Esther TORRENTE and Rita SCARPELLI and Giovanni BOTTEGONI and Tiziano BANDIERA and Marina VERONESI",

year = "2015",

language = "English",

type = "Patent",

note = "WO2015/52283",

}

TY - PAT

T1 - Diarylalkylamine REV-ERB antagonists and their use as medicaments

AU - Fondazione Istituto Italiano di Tecnologia

AU - GRIMALDI, Benedetto

AU - TORRENTE, Esther

AU - SCARPELLI, Rita

AU - BOTTEGONI, Giovanni

AU - BANDIERA, Tiziano

AU - VERONESI, Marina

PY - 2015

Y1 - 2015

N2 - The present invention relates to compounds of Formula (I) or pharmaceutically acceptable salts or solvates thereof : It further discloses a pharmaceutical composition comprising the compounds of Formula (I) and their uses as anti-proliferative and pro-apoptotic agents for cancer therapy.

AB - The present invention relates to compounds of Formula (I) or pharmaceutically acceptable salts or solvates thereof : It further discloses a pharmaceutical composition comprising the compounds of Formula (I) and their uses as anti-proliferative and pro-apoptotic agents for cancer therapy.

M3 - Patent

M1 - WO2015/52283

ER -

Diarylalkylamine REV-ERB antagonists and their use as medicaments

Abstract

UN SDGs

Fingerprint

Cite this